News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Dana-Farber Lank Center for GU Oncology Research Digest for the week of February 15 – 21
Dana-Farber Cancer Institute /LinkedIn
Feb 25, 2025, 09:48

Dana-Farber Lank Center for GU Oncology Research Digest for the week of February 15 – 21

Dana-Farber Lank Center for Genitourinary Oncology shared a post on X:

“GU Research Digest for the week of February 15 – 21: a selection of publications about GU cancers in high-impact journals. Search the PMIDs on PubMed to read!”

Genitourinary/Immunotherapy/General

“Treatment strategies in human papillomavirus-related advanced penile cancer”

Authors: Mattia Longoni et al.

Dana-Farber Lank Center for GU Oncology Research Digest for the week of February 15 - 21

Renal

“Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial”

Authors: Sangeeta Goswami et al.

Dana-Farber Lank Center for GU Oncology Research Digest for the week of February 15 - 21

Bladder/Urothelial

“Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts”

Authors: Lilian Marie Boll et al.

Dana-Farber Lank Center for GU Oncology Research Digest for the week of February 15 - 21

“COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts”

Authors: Sumanta Pal et al.

Dana-Farber Lank Center for GU Oncology Research Digest for the week of February 15 - 21

“Asparagine drives immune evasion in bladder cancer via RIG-I stability and type I IFN signaling”

Authors: Wenjie Wei et al.

Dana-Farber Lank Center for GU Oncology Research Digest for the week of February 15 - 21

“Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial”

Authors: Xavier Garcia-Del-Muro et al.

Dana-Farber Lank Center for GU Oncology Research Digest for the week of February 15 - 21

Prostate

“Engineering nanozyme immunomodulator with magnetic targeting effect for cascade-enzyodynamic and ultrasound-reinforced metallo-immunotherapy in prostate carcinoma”

Authors: Yandong Wang et al.

Dana-Farber Lank Center for GU Oncology Research Digest for the week of February 15 - 21

“Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials”

Authors: A Dal Pra et al.

Dana-Farber Lank Center for GU Oncology Research Digest for the week of February 15 - 21

“EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models”

Authors: Patrizia Porazzi et al.

Dana-Farber Lank Center for GU Oncology Research Digest for the week of February 15 - 21

“Validation of a digital pathology-based multimodal artificial intelligence biomarker in a prospective, real-world prostate cancer cohort treated with prostatectomy”

Authors: Anders Bjartell et al.

Dana-Farber Lank Center for GU Oncology Research Digest for the week of February 15 - 21

“Integrating the environmental and genetic architectures of aging and mortality”

Authors: Austin Argentieri et al.

Dana-Farber Lank Center for GU Oncology Research Digest for the week of February 15 - 21

“Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases”

Authors: Jonathan Mitchell et al.

Dana-Farber Lank Center for GU Oncology Research Digest for the week of February 15 - 21

“Tumour-wide RNA splicing aberrations generate actionable public neoantigens”

Authors: Darwin Kwok et al.

Dana-Farber Lank Center for GU Oncology Research Digest for the week of February 15 - 21

“Clinical and Translational Results from PORTER, a Multi-cohort Phase 1 Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer”

Authors: Matthew Galsky et al.

Dana-Farber Lank Center for GU Oncology Research Digest for the week of February 15 - 21

More posts featuring Dana-Farber Lank Center for Genitourinary Oncology.

Anders Bjartell Austin Argentieri bladder cancer cancer Dal Pra Dana-Farber Lank Center for Genitourinary Oncology Darwin Kwok human papillomavirus Jonathan Mitchell Lilian Marie Boll Matthew Galsky Mattia Longoni OncoDaily Oncology Patrizia Porazzi prostate cancer renal cell carcinoma Research Digest Sangeeta Goswami Sumanta Pal Wenjie Wei Xavier Garcia-del-Muro Yandong Wang
Special Coverage
Science
Feb 25, 2025, 09:48
Dana-Farber Lank Center for GU Oncology Research Digest for the week of February 15 - 21
Science
Feb 25, 2025, 09:44
Laura Bukavina: 12-year outcomes of cystectomies in NMIBC
Blog
Feb 25, 2025, 09:44
How can oncologists protect their own well-being? - ESMO
Blog
Feb 25, 2025, 09:40
Yüksel Ürün: Cancer survivors face higher risk of cardiovascular disease
Blog
Feb 25, 2025, 09:39
Abhishek Shankar: Honored to have been part of the Illuminate Oncology Town Hall 2.0
Blog
Feb 25, 2025, 09:36
Melvin Chua: Pleased to see ASCOBT returning next year to the island of Singapore
Blog
Feb 25, 2025, 09:34
Lung Cancer in Women and Nonsmokers - Lung Cancer Europe
Insight
Feb 25, 2025, 09:33
Paolo Tarantino: Does Trop2 expression matter in the context of Dato-DXd treatment of mBC?
Blog
Feb 25, 2025, 09:30
Working together to make a difference - Cancer Institute NSW
Blog
Feb 25, 2025, 09:19
Biniyam Tefera Deressa: The V.O.I.C.E. initiative is coming with a transformative change in cancer care
Science
Feb 25, 2025, 09:18
Yüksel Ürün: A new mRNA cancer vaccine shows promise in pancreatic cancer
Science
Feb 25, 2025, 09:17
Lena Wirth: TLS and T-Cell Exhaustion Drive PD-1 Blockade Responce in RCC